

## AroCell's Nomination Committee has had its first meeting

**Uppsala, March 17, 2020. The Chairman of AroCell AB (publ) has established a Nomination Committee for the Annual General Meeting, which is planned to be held on May 6, 2020. The Nomination Committee is appointed by the three largest shareholders that have accepted the invitation to participate in the committee.**

The following members have been identified as the three largest shareholders that are willing to participate in the Nomination Committee and they have appointed the following members:

- Mikael Lönn, represents his own shares
- Bernhard Tribukait, represents his own shares
- Jon Eiken, represents his own shares
- Claes Post, Chairman of AroCell AB

In total, the Nomination Committee represents approximately 10% of the total number of shares and votes in the company.

The Nomination Committee elected Jon Eiken as chairman.

The Committee's proposal will be presented in Notice of Annual General Meeting 2020 that will be held in Uppsala the 6 of May 2020 as well as on the company #s webpage, [www.arocell.com](http://www.arocell.com). Shareholders that wish to leave suggestions to the Nomination Committee can do so by sending an email to [info@arocell.com](mailto:info@arocell.com) (header: AroCell #s Nomination Committee) or via regular mail to

AroCell AB  
Att: Valberedning  
Virdings allé 32B  
754 50 UPPSALA

### Contacts

Michael Brobjer, CEO  
Telephone: +46(0)18 50 30 20  
E-mail: [michael.brobjer@arocell.com](mailto:michael.brobjer@arocell.com)

## About AroCell

---

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: [Certifiedadviser@redeye.se](mailto:Certifiedadviser@redeye.se), +46 (0)8 121 576 90. For more information; [www.arocell.com](http://www.arocell.com)

## Attachments

---

[AroCell's Nomination Committee has had its first meeting](#)